Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.75 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15639461 | 0.89 | ROCK2 (0.77) | ROCK2ROCK1KDR | |
| SCHEMBL15639826 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL15639136 | 0.86 | KDR (0.73) | ROCK2ROCK1KDR | |
| SCHEMBL17041171 | 0.85 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL17041167 | 0.85 | ROCK2 (0.68) | ROCK2ROCK1 | |
| SCHEMBL32670264 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL15639264 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1 | |
| SCHEMBL32670185 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1KDR | |
| SCHEMBL15639115 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1KDR | |
| SCHEMBL15638684 | 0.83 | ROCK2 (0.71) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815820-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885KDR 2135/4885 |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | ROCK2 1/4885ROCK1 5/4885KDR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.